What is deuterated apixaban?
Deuterated apixaban is a modified version of the anticoagulant drug apixaban. It is created by replacing specific hydrogen atoms in the apixaban molecule with deuterium atoms. This structural change can alter the drug's metabolic profile, potentially leading to different pharmacokinetic properties [1].
Why are companies developing deuterated apixaban?
The development of deuterated apixaban is driven by the potential to improve upon the original apixaban molecule. By altering how the drug is metabolized by the body, researchers aim to achieve benefits such as increased bioavailability, reduced variability in drug levels among patients, and potentially fewer drug-drug interactions [1]. These modifications can be a strategy to create new intellectual property and extend market exclusivity for the therapeutic compound.
When does the patent for apixaban expire?
The primary patents protecting apixaban (Eliquis) have an estimated expiry in the coming years. According to DrugPatentWatch.com, the compound patent for apixaban is expected to expire around 2026 in major markets like the United States and Europe [2]. However, there may be other patents related to formulations, manufacturing processes, or specific uses that could extend market exclusivity further.
Can deuterated apixaban circumvent existing apixaban patents?
Deuterated apixaban represents a new chemical entity, meaning its specific molecular structure with deuterium atoms is distinct from the original apixaban. Companies developing deuterated versions would likely seek their own patents for this novel compound. This strategy allows for the development of a potentially improved drug that may not infringe upon the original apixaban compound patent, but it also navigates the landscape of patent expiration for the original drug [1][2].
What are the potential benefits of deuterated apixaban over standard apixaban?
The primary goal of deuteration in apixaban is to alter its metabolism. Specifically, deuterium atoms are heavier than hydrogen atoms and can slow down the rate at which certain enzymes break down the drug in the liver [1]. This metabolic shift could lead to:
* Increased Stability: The drug may remain in the body for longer periods, potentially allowing for less frequent dosing or more consistent therapeutic levels.
* Reduced Variability: Patients often metabolize drugs differently. Deuteration might lead to more predictable drug concentrations across a patient population, reducing the need for dose adjustments.
* Fewer Drug Interactions: If deuterated apixaban is metabolized through different pathways than standard apixaban or other drugs, it could lead to a reduced risk of harmful interactions.
What is the clinical status of deuterated apixaban?
Information regarding the specific clinical development status and trial data for deuterated apixaban is proprietary to the companies developing it. However, the pursuit of deuterated versions of existing drugs indicates ongoing research and development efforts in the pharmaceutical industry.
Who is developing deuterated apixaban?
Several pharmaceutical companies are known to be exploring or have explored deuterated versions of apixaban. These efforts are part of a broader trend in the industry to leverage deuterium chemistry to create next-generation therapeutics. Specific developers and their product candidates are typically disclosed through patent filings and company announcements [1][2].
Sources:
[1] DrugPatentWatch.com
[2] https://drugpatentwatch.com/blog/new-drug-patents/deuterated-apixaban-patent-evergreening-strategy